Abstract
Purpose of Review
Syringe access programs (SAPs) are cornerstone harm reduction interventions for combatting the national opioid epidemic. The goal of this paper is to describe effective advocacy strategies for enacting syringe decriminalization legislation to foster the expansion of SAPs in high-need areas amidst political opposition.
Recent Findings
Decades or research shows that SAPs prevent the transmission of HIV among people who inject drugs (PWID) and are a cost-effective tool for linking PWID to medical care, health education, and social services. In the USA, state laws criminalizing distribution and possession of syringes impede the expansion of SAPs into areas where they are sorely needed.
Summary
In 2016, North Carolina became the first state to legalize SAPs with a Republican super majority. This paper distills strategies for community organizations seeking to advance syringe decriminalization legislation in politically conservative states with histories of prioritizing punitive sanctions over public health responses to drug use.
Similar content being viewed by others
References
Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–8.
Onofrey S, Aneja J, Haney GA, Nagami EH, DeMaria A, Lauer GM, et al. Underascertainment of acute hepatitis C virus infections in the US surveillance system a case series and chart review. Ann Intern Med. 2015;163(4):254–61.
Rhea S, Fleischauer A, Foust E, Davies M. Hepatitis C in North Carolina two epidemics with one public health response. N C Med J. 2016;77(3):190–2.
Centers for Disease Control and Prevention. HIV Surveillance Report, 2015; vol. 27. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2016. Accessed October 24, 2017.
AIDS Vu. North Carolina Profile. https://aidsvu.org/state/north-carolina/ Accessed 20 Oct. 2017.
Proescholdbell S. Opioid overdose and North Carolina’s public health and prevention strategies. https://www.ncleg.net/DocumentSites/Committees/NCCFTF/Presentations/2016-2017/Overdose%20Update%20Proescholdbell%2010-20-16.pdf. Accessed 20 Oct. 2017.
Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102–23.
Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med. 2005;353(18):1945–54.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.
Keeshin SW, Feinberg J. Endocarditis as a marker for new epidemics of injection drug use. Am J Med Sci. 2016;352(6):609–14.
North Carolina HIV/STD/Hepatitis Surveillance Unit. (2017). 2016 North Carolina HIV/STD/hepatitis surveillance report. North Carolina Department of Health and Human Services, Division of Public Health, Communicable Disease Branch. Raleigh, North Carolina. http://epi.publichealth.nc.gov/cd/stds/figures/std16rpt_rev2.pdf. Accessed 1 Oct. 2017.
Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329–41.
Bastos FI, Strathdee SA. Evaluating effectiveness of syringe exchange programmes: current issues and future prospects. Soc Sci Med. 2000;51(12):1771–82.
Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr. 1998;18:S37–44.
Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271(2):115–20.
Wodak, A., Cooney, A., & World Health Organization. (2004). Effectiveness of sterile needle and syringe programming in reducing HIV.
Holtzman D, Barry V, Ouellet LJ, Des Jarlais DC, Vlahov D, Golub ET, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994–2004. Prev Med. 2009;49(1):68–73.
Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–63.
Strathdee SA, Ricketts EP, Huettner S, Cornelius L, Bishai D, Havens JR, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225–32.
Strathdee SA, Celentano DD, Shah N, Lyles C, Stambolis VA, Macalino G, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. Journal of Urban Health. 1999;76(4):448–60.
Marx MA, Crape B, Brookmeyer RS, Junge B, Latkin C, Vlahov D, et al. Trends in crime and the introduction of a needle exchange program. Am J Public Health. 2000;90(12):1933–6.
Galea S, Ahern J, Fuller C, Freudenberg N, Vlahov D. Needle exchange programs and experience of violence in an inner city neighborhood. J Acquir Immune Defic Syndr. 2001;28(3):282–8.
The Centers for Disease Prevention and Control. Syringe Services Programs (SSPs) for People Who Inject Drugs (PWID). Available at https://www.cdc.gov/nchhstp/dear_colleague/2016/dcl-033016-syringe-services-programs-for-pwid.html. Accessed November 8, 2017.
The American Public Health Association. Policy Statement. Syringe and Needle Exchange and HIV Disease.
American Society of Addiction Medicine. Public Policy Statement on Access to Sterile Syringes and Needle (2005). https://www.asam.org/docs/default-source/public-policy-statements/1access-syringes-12-00.pdf?sfvrsn=90a8c1b2_0. Accessed 20 Oct. 2017.
National Association of City and County Health Officials. Statement of Policy. “Syringe Service Programs” May 2009/ https://www.naccho.org/uploads/downloadable-resources/Policy-and-Advocacy/05-09-Syringe-Services-Programs.pdf. Accessed 20 Oct. 2017.
North American Syringe Exchange Network. https://nasen.org/directory/. Accessed 20 Oct. 2017.
Wejnert C. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs—United States. MMWR Morb Mortal Wkly Rep. 2016;65:1336–42.
Heller D, Paone D. Access to sterile syringes for injecting drug users in new York City: politics and perception (1984–2010). Substance Use & Misuse. 2011;46(2–3):140–9.
Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction. 2009;104(9):1441–6.
Friedman SR, Southwell M, Bueno R, Paone D, Byrne J, Crofts N. Harm reduction—a historical view from the left. International Journal of Drug Policy. 2001;12(1):3–14.
Buchanan D, Shaw S, Ford A, Singer M. Empirical science meets moral panic: an analysis of the politics of needle exchange. J Public Health Policy. 2003:427–44.
The Consolidated Appropriations Act (2016). Division H, Sec 520. https://www.congress.gov/114/bills/hr2029/BILLS-114hr2029enr.pdf. Accessed 8 Nov. 2017.
Department of Health and Human Services Implementation Guidance to Support Certain Components of Syringe Services Programs, 2016. https://www.hiv.gov/sites/default/files/hhs-ssp-guidance.pdf. Accessed 8 Nov. 2017.
National Conference of State Legislatures. State Partisan Composition in 2017. http://www.ncsl.org/Portals/1/Documents/Elections/Legis_Control_2017_November%208th_9am.pdf. Accessed 8 Nov. 2017.
Taussig JA, Weinstein B, Burris S, Jones TS. Syringe laws and pharmacy regulations are structural constraints on HIV prevention in the US. AIDS. 2000;14:S47–51.
Beletsky L, Cochrane J, Sawyer AL, Serio-Chapman C, Smelyanskaya M, Han J, et al. Police encounters among needle exchange clients in Baltimore: drug law enforcement as a structural determinant of health. Am J Public Health. 2015;105(9):1872–9.
Bramson H, Des Jarlais DC, Arasteh K, Nugent A, Guardino V, Feelemyer J, et al. State laws, syringe exchange, and HIV among persons who inject drugs in the United States: history and effectiveness. J Public Health Policy. 2015;36(2):212–30.
Preventing HIV and Hepatitis C Among people who inject drugs: public funding for syringe services programs makes the difference. Issue brief. April 2017.amfAR. The Foundation for AIDS Research http://www.amfar.org/uploadedFiles/_amfarorg/On_the_Hill/amfAR_SSP_Issue_Brief_April_2017-update.pdf. Accessed 8 Nov. 2017.
General Assembly of North Carolina. House Bill 972 / S.L. 2016–88. http://www.ncleg.net/Sessions/2015/Bills/House/HTML/H972v8.html. Accessed 8 Nov. 2017.
Kentucky Harm Reduction and Syringe Exchange Program (HRSEP) Guidelines for Local Health Departments Implementing Needle Exchange Programs. http://chfs.ky.gov/NR/rdonlyres/E7FBC3DC-E365-4CD8-93BF-FA797052303A/0/HRSEPGuidelinesLongVersionFINAL.pdf. Accessed 8 Nov. 2017.
Kerr T, Small W, Wood E. The public health and social impacts of drug market enforcement: a review of the evidence. International journal of drug policy. 2005;16(4):210–20.
Burris S, Blankenship KM, Donoghoe M, Sherman S, Vernick JS, Case P, et al. Addressing the “risk environment” for injection drug users: the mysterious case of the missing cop. The Milbank Quarterly. 2004;82(1):125–56.
Cooper H, Moore L, Gruskin S, Krieger N. The impact of a police drug crackdown on drug injectors’ ability to practice harm reduction: a qualitative study. Soc Sci Med. 2005;61(3):673–84.
Bluthenthal RN, Ridgeway G, Schell T, Anderson R, Flynn NM, Kral AH. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction. 2007;102(4):638–46.
Bluthenthal RN, Malik R, Grau LE, Singer M, Marshall P, Heimer R. Sterile syringe access conditions and variations in HIV risks among drug injectors in three cities. Addiction. 2004;99:1136–46.
Kral AH, Anderson R, Flynn NM, Bluthenthal RN. Injection risk behaviors among clients of syringe exchange programs with different syringe dispensation policies. Journal of Acquired Immune Deficiency Syndrome. 2004;37:1307–12.
Strengthen Opioid Misuse Prevention (STOP)Act. https://www.ncleg.net/Sessions/2017/Bills/Senate/PDF/S175v1.pdf. Accessed 8 Nov. 2017.
Davis CS, Johnston J, de Saxe Zerden L, Clark K, Castillo T, Childs R. Attitudes of North Carolina law enforcement officers toward syringe decriminalization. Drug Alcohol Depend. 2014;144:265–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on The Global Epidemic
Rights and permissions
About this article
Cite this article
Cloud, D.H., Castillo, T., Brinkley-Rubinstein, L. et al. Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition. Curr HIV/AIDS Rep 15, 276–282 (2018). https://doi.org/10.1007/s11904-018-0397-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11904-018-0397-9